Literature DB >> 17065927

Interferon therapy for ocular disease.

Friederike Mackensen1, Regina Max, Matthias D Becker.   

Abstract

PURPOSE OF REVIEW: Interferons were first known for their antiviral action. Immunomodulatory therapy with interferons has been studied in various diseases. This paper summarizes the role and presumed mechanisms of action of type 1 interferons in the treatment of ocular disease. RECENT
FINDINGS: Preliminary data show beneficial effects of interferons in ocular disease such as Behçet disease and multiple sclerosis-associated uveitis in terms of visual acuity, intraocular inflammation activity, and chronic macular edema. Another mode of application is topical as an adjuvant treatment in viral keratitis or ocular surface malignancies.
SUMMARY: Interferons are gaining a place in the treatment of ocular disease. Evidence is growing of their potential in ocular Behçet disease and multiple sclerosis-associated uveitis. Randomized, controlled clinical trials are needed to confirm this observation. Further insights into the complex mechanisms of action of interferons in health and disease will increase understanding of their mechanisms of action as a therapeutic substance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17065927     DOI: 10.1097/ICU.0b013e328010ab35

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  5 in total

1.  Anti-interferon alpha antibodies and autoantibodies in patients with Behçet's disease uveitis treated with recombinant human interferon alpha-2a.

Authors:  Özlem Aydinoglu-Candan; Bilge Araz-Erşan; Ahmet Gul; Selim Badur; Ilknur Tugal-Tutkun
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-12-12       Impact factor: 3.117

2.  Etiology and treatment of the inflammatory causes of cystoid macular edema.

Authors:  Hyung Cho; Assumpta Madu
Journal:  J Inflamm Res       Date:  2009-10-02

3.  The efficacy of intravitreal interferon alpha-2b for the treatment of experimental endotoxin-induced uveitis.

Authors:  Mehrdad Afarid; Hamid Lashkarizadeh; Mohammad J Ashraf; Mohammad Hossein Nowroozzadeh; Sayed M Shafiee
Journal:  Indian J Ophthalmol       Date:  2016-05       Impact factor: 1.848

4.  Interferons and their potential in the treatment of ocular inflammation.

Authors:  Friederike Mackensen; Regina Max; Matthias D Becker
Journal:  Clin Ophthalmol       Date:  2009-10-19

5.  Is Interferon α-2b 1 MillionIU/mL Truly Better Than Tacrolimus 0.03% for Steroid-Resistant VKC ?: Our 2-Year Experience at a Tertiary Health-Care Centre.

Authors:  Sukriti Gupta; Priyanka Singh; Mrityunjay Singh; Mayuresh Naik; Kartikeya Srivastava
Journal:  Clin Ophthalmol       Date:  2021-07-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.